PARADOXICAL FALLS IN HDL-C WITH FENOFIBRATE

被引：0
|
作者：
Magee, G. [1 ]
Sharpe, P. [1 ]
机构：
[1] Craigavon Area Hosp, Dept Clin Biochem, Portadown, Co Armagh, North Ireland
来源：
ATHEROSCLEROSIS SUPPLEMENTS | 2008年 / 9卷 / 01期
关键词：
D O I：
10.1016/S1567-5688(08)70768-2
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：192 / 192
页数：1
相关论文
共 50 条
  • [1] A review of paradoxical HDL-C responses to fenofibrate, illustrated by a case report
    Schofield, Jonathan D.
    Liu, Yifen
    France, Michael W.
    Sandle, Lance
    Soran, Handrean
    JOURNAL OF CLINICAL LIPIDOLOGY, 2014, 8 (04) : 455 - 459
  • [2] Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial
    Linz, Peter E.
    Lovato, Laura C.
    Byington, Robert P.
    O'Connor, Patrick J.
    Leiter, Lawrence A.
    Weiss, Daniel
    Force, Rex W.
    Crouse, John R.
    Ismail-Beigi, Faramarz
    Simmons, Debra L.
    Papademetriou, Vasilios
    Ginsberg, Henry N.
    Elam, Marshall B.
    DIABETES CARE, 2014, 37 (03) : 686 - 693
  • [3] Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment
    Shetty, C.
    Balasubramani, M.
    Capps, N.
    Milles, J.
    Ramachandran, S.
    DIABETIC MEDICINE, 2007, 24 (01) : 94 - 97
  • [4] Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
    Farnier, Michel
    Dong, Qian
    Shah, Arvind
    Johnson-Levonas, Amy O.
    Brudi, Philippe
    LIPIDS IN HEALTH AND DISEASE, 2011, 10
  • [5] Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
    Michel Farnier
    Qian Dong
    Arvind Shah
    Amy O Johnson-Levonas
    Philippe Brudi
    Lipids in Health and Disease, 10
  • [6] Neutrophil/HDL-C, Lymphocyte/HDL-C and Monocyte/HDL-C in subjects with asymptomatic carotid atherosclerosis
    Caimi, Gregorio
    Lo Presti, Rosalia
    Urso, Caterina
    Brucculeri, Salvatore
    Carlisi, Melania
    CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, 2024, 88 (01) : 1 - 11
  • [7] Hypertriglyceridemia and Low HDL-C Predicts Fenofibrate Response in The ACCORD-Lipid Trial
    Elam, Marshall B.
    Lovato, Laura C.
    Byington, Robert P.
    Bonds, Denise
    Leiter, Lawrence
    Crouse, John R.
    Linz, Peter
    Marcovina, Santica
    O'Connor, Patrick J.
    Ginsberg, Henry N.
    CIRCULATION, 2010, 122 (21)
  • [8] HDL-C and Mortality
    Salonen, Jukka T.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (13) : 1759 - 1759
  • [9] Role of Lipid Profile and Its Relative Ratios (Cholesterol/HDL-C, Triglyceride/HDL-C, LDL-C/HDL-C, WBC/HDL-C, and FBG/HDL-C) on Admission Predicts In-Hospital Mortality COVID-19
    Mohammadshahi, Jafar
    Ghobadi, Hassan
    Matinfar, Golchin
    Boskabady, Mohammad Hossein
    Aslani, Mohammad Reza
    JOURNAL OF LIPIDS, 2023, 2023
  • [10] Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels
    Phuntuwate, Wimon
    Suthisisang, Chuthamanee
    Koanantakul, Banhan
    Chaloeiphap, Preecha
    Mackness, Bharti
    Mackness, Mike
    ATHEROSCLEROSIS, 2008, 196 (01) : 122 - 128
12345